COVID‑19 has caused unprecedented societal turmoil, triggering a rapid, still ongoing,
transformation of healthcare provision on a global level. In this new landscape, it is highly …

Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …

With a lifetime risk estimated to be one in eight in industrialized countries, breast cancer is
the most frequent type of cancer among women worldwide. Patients are often treated with …

Triple-negative breast cancer (TNBC) lacks expression of estrogen receptor (ER),
progesterone receptor (PR) and HER2 gene. It comprises approximately 15-20% of breast …

Cancer cells undergo many different alterations during their transformation, including
genetic and epigenetic events. The controlled division of healthy cells can be impaired …

Chemotherapy has represented the standard therapy for unresectable or metastatic
urothelial carcinoma for more than 20 years. The growing knowledge of the interaction …

Recent studies highlight the great potential impact of HDAC inhibitors (HDACis) in
suppressing TNBC, even though clinical trials including a single HDACis demonstrated …

Epithelial to mesenchymal transition (EMT) is the process whereby a polarized epithelial cell
ceases to maintain cell-cell contacts, loses expression of characteristic epithelial cell …

Background/Aim: There is a strong association between malignancy and histone
deacetylases (HDACs). Histone deacetylase inhibitors (HDACIs) are now being tested as …

Thyroid cancer is the most common malignancy of the endocrine system with a steadily
rising incidence. The term “thyroid cancer” encompasses a spectrum of subtypes, namely …